Debra Auguste

Last updated
Debra Auguste
Debra Auguste at 2012 NIH PECASE.jpg
Auguste upon receiving the PECASE for 2012
NationalityAmerican
Alma mater Massachusetts Institute of Technology (S.B.)
Princeton University (M.A., Ph.D.)
Known forBiocompatible liposome drug delivery design
AwardsElected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) (2020)
Presidential Early Career Award for Scientists and Engineers (PECASE) in the United States Department of Health and Human Services (2012)
National Institutes of Health Director’s New Innovator Award (2012)
50 Most Influential African-Americans in Technology List (2010)
Scientific career
FieldsChemical engineering, biomedical engineering
Institutions Northeastern University

Debra Auguste is an American chemical engineer and professor at Northeastern University in the department of chemical engineering. [1] Auguste is dedicated to developing treatments for triple negative breast cancer, one of the most aggressive and fatal cancers that disproportionately affects African American women. Her lab characterizes biomarkers of triple negative breast cancer and develops novel biocompatible therapeutic technologies to target and destroy metastatic cancer cells. Auguste received the 2012 Presidential Early Career Award for Scientists and Engineers and in 2010 was named in the 50 Most Influential African-Americans in Technology. In 2020, Auguste became an Elected Fellow of the American Institute for Medical and Biological Engineering.

Contents

Early life and education

Auguste pursued her undergraduate studies at the Massachusetts Institute of Technology in 1995. [2] She majored in chemical engineering and graduated in 1999 with her Bachelor of Science. [2] Following her undergraduate degree, Auguste pursued her Master's and her PhD in chemical engineering at Princeton University. [3] She studied under the mentorship of Robert K. Prud’homme, where she designed and tested novel liposome structures for potential use in drug delivery platforms. [4] She worked on creating hydrophobically-modified polyethylene glycol (PEG) polymers that can evade complement binding, an immune molecule that tags pathogens for immune system clearance and destruction. [5] After completing her master's in 2004, Auguste further optimized the design of drug delivery liposomes with PEG protective layers so that they could be enabled to lose their protective layer once inside the cell to fuse with the endosome and release contents into the cell. [6] She was able to design liposomes that conjugate PEG and maintain them at pH levels similar to blood, and then dissociate them once they arrive at pH levels below 7.4. [6] Auguste completed her PhD in 2005. [3]

Following her PhD training, Auguste began her postdoctoral fellowship at the Massachusetts Institute of Technology, working under the mentorship of Robert Langer. [3] She worked in the department of chemical engineering optimizing liposomal drug delivery methods to deliver short interfering RNA (siRNA) to mediate gene knockdown. [7] She built the liposomes based on her previous work using pH-dependent liposomes with the PEG coating to prevent immune opsonization, but with the added ability to deliver siRNA to the endosome of the cell. [7] Auguste also helped to co-author the Third Edition of the Principals of Tissue Engineering Textbook. [8] Auguste completed her postdoctoral training in 2006. [4]

Career and research

Auguste was appointed to the faculty at Harvard University in 2006, becoming an assistant professor of bioengineering in the Harvard School of Engineering Applied Sciences. [9] As the principal investigator of the Auguste Lab, Auguste's research program focused on developing novel biomaterials for drug delivery systems through studying mechanisms of cell development and exploring how these mechanisms are perturbed by environmental signals. [9] In 2011, Auguste was appointed to lecturer in the department of surgery at Harvard Medical School as well as assistant professor in the Department of Vascular Biology at Boston Children's Hospital. [10] At this time she discovered a staggering statistic that changed the course of her research program. [10] After finding that African American women have the highest breast cancer mortality rate, she began focusing on understanding which surface proteins might differ on the metastatic breast cancer cells of African American women versus other ethnic groups with the goal of drug design targeting that protein in the future. [10]

In 2012, Auguste became an associate professor of biomedical engineering at the City University of New York while still holding her Assistant Professorship at Harvard Medical School. [11] She worked in the Grove School of Engineering where her lab continued to focus on the discovery molecular targets for triple negative breast cancer as well as novel therapies to inhibit breast cancer metastasis. [11]

In 2016, Auguste became a professor at Northeastern University in the college of engineering, department of chemical engineering. [12] Her lab continues to focus on developing novel biocompatible drug delivery platforms, with an emphasis on drugs for treatment of triple negative breast cancer. [2]

In addition to her faculty position and role as the principal investigator of the Auguste Lab at Northeastern, Auguste is also a member of the American Chemical Society, American Institute of Chemical Engineers, Biomedical Engineering Society, Materials Research Society, and is an associate editor for the Annals of Biomedical Engineering from the Biomedical Engineering Society. [2]

Triple negative breast cancer drug development

Auguste's lab focuses on characterizing novel therapeutic targets for triple negative breast cancer and designing biocompatible drug delivery systems for treatment. [13] Triple negative breast cancer is the most common cancer affecting African American women and it also remains the most difficult to test and treat due to the lack biomarkers. [13] In 2014, Auguste and her lab found that ICAM-1 represents a marker for triple negative breast cancer as well as a potential molecular target for therapy. [14] Their work was published in the Proceedings of the National Academy of Sciences in 2014. [14]

Following this finding, Auguste and her team sought to determine an improved way of identifying and targeting triple negative breast cancer (TNBC) cells that did not rely on just one cellular marker. [13]  They instead looked at the ratio of ICAM-1 to another marker of TNBC, epithelial growth factor (EGFR), in order to design a therapeutic with the ability to bind multiple ligands at once to selectively target and identify TNBC cells. [15] The complementary targeting of specific ligand ratios was enabled with a dual complementary liposome that specifically binds the ratio of EGFR and ICAM-1 on tumor cells. [15] They showed that binding was effective and also that binding decreased receptor signalling and was able to interfere enough with cellular processes that it could minimize metastasis. [15] Further the specificity of binding will enable targeted drug delivery to TNBC cells in the future as well. [16] Due to the efficacy and promising potential of this technology, Auguste and her colleagues filed a patent for these cancer targeting liposomes in 2018. [17]

Auguste, along with her colleagues at Boston Children's Hospital, has also pioneered a novel gene editing approach to treating TNBC. [18] The developed a tumor-targeted nanolipogel system which targets tumors and enables CRISPR mediated knockout of Lipocalin2, a known breast cancer oncogene. [18] This method was able to reduce tumor growth by 77% without toxicity to healthy tissues. [18] The system again uses the approach of targeting ICAM-1 on TNBC cells via antibody binding of the liposome to the cells in order to specifically infect tumor cells. [19] This article was also published in the Proceedings of the National Academy of Sciences. [19]

Awards and honors

Select publications

Related Research Articles

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

<span class="mw-page-title-main">Cationic liposome</span>

Cationic liposomes are spherical structures that contain positively charged lipids. Cationic liposomes can vary in size between 40 nm and 500 nm, and they can either have one lipid bilayer (monolamellar) or multiple lipid bilayers (multilamellar). The positive charge of the phospholipids allows cationic liposomes to form complexes with negatively charged nucleic acids through ionic interactions. Upon interacting with nucleic acids, cationic liposomes form clusters of aggregated vesicles. These interactions allow cationic liposomes to condense and encapsulate various therapeutic and diagnostic agents in their aqueous compartment or in their lipid bilayer. These cationic liposome-nucleic acid complexes are also referred to as lipoplexes. Due to the overall positive charge of cationic liposomes, they interact with negatively charged cell membranes more readily than classic liposomes. This positive charge can also create some issues in vivo, such as binding to plasma proteins in the bloodstream, which leads to opsonization. These issues can be reduced by optimizing the physical and chemical properties of cationic liposomes through their lipid composition. Cationic liposomes are increasingly being researched for use as delivery vectors in gene therapy due to their capability to efficiently transfect cells. A common application for cationic liposomes is cancer drug delivery.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

<span class="mw-page-title-main">Bacillus virus phi29</span> Species of virus

Bacillus virus Φ29 is a double-stranded DNA (dsDNA) bacteriophage with a prolate icosahedral head and a short tail that belongs to the genus Salasvirus, order Caudovirales, and family Salasmaviridae. They are in the same order as phages PZA, Φ15, BS32, B103, M2Y (M2), Nf, and GA-1. First discovered in 1965, the Φ29 phage is the smallest Bacillus phage isolated to date and is among the smallest known dsDNA phages.

Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19, triple negative breast cancer, and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015. In February 2018, Cytodyn Inc reported that the primary endpoint had been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection.

<span class="mw-page-title-main">Arginylglycylaspartic acid</span> Chemical compound

Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. The discovery of RGD and elucidation of how RGD binds to integrins has led to the development of a number of drugs and diagnostics, while the peptide itself is used ubiquitously in bioengineering. Depending on the application and the integrin targeted, RGD can be chemically modified or replaced by a similar peptide which promotes cell adhesion.

Microbubbles are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, medicine, life science, and food technology. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

<span class="mw-page-title-main">Sonodynamic therapy</span>

Sonodynamic therapy (SDT) is a noninvasive treatment, often used for tumor irradiation, that utilizes a sonosensitizer and the deep penetration of ultrasound to treat lesions of varying depths by reducing target cell number and preventing future tumor growth. Many existing cancer treatment strategies cause systemic toxicity or cannot penetrate tissue deep enough to reach the entire tumor; however, emerging ultrasound stimulated therapies could offer an alternative to these treatments with their increased efficiency, greater penetration depth, and reduced side effects. Sonodynamic therapy could be used to treat cancers and other diseases, such as atherosclerosis, and diminish the risk associated with other treatment strategies since it induces cytotoxic effects only when externally stimulated by ultrasound and only at the cancerous region, as opposed to the systemic administration of chemotherapy drugs.

<span class="mw-page-title-main">Nanocarrier</span>

A nanocarrier is nanomaterial being used as a transport module for another substance, such as a drug. Commonly used nanocarriers include micelles, polymers, carbon-based materials, liposomes and other substances. Nanocarriers are currently being studied for their use in drug delivery and their unique characteristics demonstrate potential use in chemotherapy. This class of materials was first reported by a team of researchers of University of Évora, Alentejo in early 1960's, and grew exponentially in relevance since then.

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Sacituzumab govitecan</span> Antibody-drug conjugate

Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

<span class="mw-page-title-main">Joseph Kost</span> Chemical engineering researcher

Joseph Kost is an Israeli academic, currently holder of The Abraham and Bessie Zacks Chair in Biomedical Engineering and the past Dean of the Faculty of Engineering Sciences at the Ben-Gurion University of the Negev.

<span class="mw-page-title-main">Antonios Mikos</span> Greek-American biomedical engineer

Antonios Georgios Mikos is a Greek-American biomedical engineer who is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He specialises in biomaterials, drug delivery, and tissue engineering.

<span class="mw-page-title-main">Bemcentinib</span> Chemical compound

Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

Shelly R. Peyton is an American chemical engineer who is the Armstrong Professional Development Professor in the Department of CHemical Engineering at the University of Massachusetts Amherst. Her research considers the development of biomaterials to investigate metastatic cancer and potential new therapies.

pH-responsive tumor-targeted drug delivery is a specialized form of targeted drug delivery that utilizes nanoparticles to deliver therapeutic drugs directly to cancerous tumor tissue while minimizing its interaction with healthy tissue. Scientists have used drug delivery as a way to modify the pharmacokinetics and targeted action of a drug by combining it with various excipients, drug carriers, and medical devices. These drug delivery systems have been created to react to the pH environment of diseased or cancerous tissues, triggering structural and chemical changes within the drug delivery system. This form of targeted drug delivery is to localize drug delivery, prolongs the drug's effect, and protect the drug from being broken down or eliminated by the body before it reaches the tumor.

<span class="mw-page-title-main">Ligand-targeted liposome</span> Ligand-targeted liposomes for use in medical applications

A ligand-targeted liposome (LTL) is a nanocarrier with specific ligands attached to its surface to enhance localization for targeted drug delivery. The targeting ability of LTLs enhances cellular localization and uptake of these liposomes for therapeutic or diagnostic purposes. LTLs have the potential to enhance drug delivery by decreasing peripheral systemic toxicity, increasing in vivo drug stability, enhancing cellular uptake, and increasing efficiency for chemotherapeutics and other applications. Liposomes are beneficial in therapeutic manufacturing because of low batch-to-batch variability, easy synthesis, favorable scalability, and strong biocompatibility. Ligand-targeting technology enhances liposomes by adding targeting properties for directed drug delivery.

References

  1. ↑ "Debra Auguste". Northeastern University College of Engineering. Retrieved 2020-08-16.
  2. 1 2 3 4 5 "Debra Auguste". Northeastern University College of Engineering. Retrieved 2020-06-26.
  3. 1 2 3 "BIOE Seminar Series: Debra Auguste | Fischell Department of Bioengineering". bioe.umd.edu. Retrieved 2020-06-26.
  4. 1 2 "Chemistry Tree - Debra T. Auguste Family Tree". academictree.org. Retrieved 2020-06-26.
  5. ↑ Auguste, Debra T.; Prud'homme, Robert K.; Ahl, Patrick L.; Meers, Paul; Kohn, Joachim (2003-10-13). "Association of hydrophobically-modified poly(ethylene glycol) with fusogenic liposomes". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1616 (2): 184–195. doi:10.1016/j.bbamem.2003.08.007. ISSN   0005-2736. PMID   14561476.
  6. 1 2 Auguste, Debra T.; Armes, Steven P.; Brzezinska, Krystyna R.; Deming, Timothy J.; Kohn, Joachim; Prud’homme, Robert K. (2006-04-01). "pH triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes". Biomaterials. 27 (12): 2599–2608. doi:10.1016/j.biomaterials.2005.08.036. ISSN   0142-9612. PMID   16380161.
  7. 1 2 Auguste, Debra T.; Furman, Kay; Wong, Andrew; Fuller, Jason; Armes, Steven P.; Deming, Timothy J.; Langer, Robert (2008-09-24). "Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes". Journal of Controlled Release. 130 (3): 266–274. doi:10.1016/j.jconrel.2008.06.004. ISSN   0168-3659. PMC   2608725 . PMID   18601962.
  8. ↑ Luo, Ying; Engelmayr, George; Auguste, Debra T.; Ferreira, Lino da Silva; Karp, Jeffrey M.; Saigal, Rajiv; Langer, Robert (2007-01-01), Lanza, Robert; Langer, Robert; Vacanti, Joseph (eds.), "Chapter Twenty-Five - Three-Dimensional Scaffolds", Principles of Tissue Engineering (Third Edition), Burlington: Academic Press, pp. 359–373, ISBN   978-0-12-370615-7 , retrieved 2020-06-26
  9. 1 2 "Debra Auguste writes letter to her younger self | Harvard John A. Paulson School of Engineering and Applied Sciences". www.seas.harvard.edu. Retrieved 2020-06-26.
  10. 1 2 3 Says, Kullback (2014-07-08). "Creative Minds: Engineering Targeted Breast Cancer Treatments". NIH Director's Blog. Retrieved 2020-06-26.
  11. 1 2 "Debra Auguste Chosen for Presidential Early Career Award | The City College of New York". www.ccny.cuny.edu. 14 July 2015. Retrieved 2020-06-26.
  12. ↑ "New Faculty Spotlight: Debra Auguste". Northeastern University College of Engineering. Retrieved 2020-06-26.
  13. 1 2 3 "Targeting Triple-Negative Breast Cancer". Northeastern University College of Engineering. Retrieved 2020-06-26.
  14. 1 2 Guo, Peng; Huang, Jing; Wang, Liya; Jia, Di; Yang, Jiang; Dillon, Deborah A.; Zurakowski, David; Mao, Hui; Moses, Marsha A.; Auguste, Debra T. (2014-10-14). "ICAM-1 as a molecular target for triple negative breast cancer". Proceedings of the National Academy of Sciences. 111 (41): 14710–14715. Bibcode:2014PNAS..11114710G. doi: 10.1073/pnas.1408556111 . ISSN   0027-8424. PMC   4205631 . PMID   25267626.
  15. 1 2 3 "Northeastern professor targets triple-negative breast cancer with new drug design". news.northeastern.edu. 2 April 2019. Retrieved 2020-06-26.
  16. ↑ Guo, Peng; Yang, Jiang; Liu, Daxing; Huang, Lan; Fell, Gillian; Huang, Jing; Moses, Marsha A.; Auguste, Debra T. (2019-03-01). "Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis". Science Advances. 5 (3): eaav5010. Bibcode:2019SciA....5.5010G. doi: 10.1126/sciadv.aav5010 . ISSN   2375-2548. PMC   6426465 . PMID   30906868.
  17. ↑ "US Patent Application for Engineered Liposomes as Cancer-Targeted Therapeutics – Patent Application (Application #20200085972 – issued March 19, 2020) - Justia Patents Search". patents.justia.com. Retrieved 2020-06-26.
  18. 1 2 3 "CRISPR gene editing may halt progression of triple-negative breast cancer". EurekAlert!. Retrieved 2020-06-26.
  19. 1 2 Guo, Peng; Yang, Jiang; Huang, Jing; Auguste, Debra T.; Moses, Marsha A. (10 September 2019). "Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel". Proceedings of the National Academy of Sciences of the United States of America. 116 (37): 18295–18303. Bibcode:2019PNAS..11618295G. doi: 10.1073/pnas.1904697116 . ISSN   1091-6490. PMC   6744870 . PMID   31451668.
  20. ↑ "Debra Auguste Dr. Debra Auguste Inducted into AIMBE College of Fellows - AIMBE" . Retrieved 2020-06-26.
  21. ↑ Hinton, Antentor O. Jr. "100 inspiring Black scientists in America". crosstalk.cell.com. Retrieved 2020-06-26.
  22. ↑ "BOARD OF DIRECTORS". bmes.org. Archived from the original on 2020-06-27. Retrieved June 25, 2020.
  23. ↑ "Debra Auguste Selected as BMES Fellow". Northeastern University College of Engineering. Retrieved 2020-06-26.
  24. ↑ "President Obama Honors Outstanding Early-Career Scientists". whitehouse.gov. 2013-12-23. Retrieved 2020-06-26.
  25. ↑ "NIH Director's New Innovator Award Program - 2012 Award Recipients | NIH Common Fund". commonfund.nih.gov. 18 September 2018. Retrieved 2020-06-26.
  26. ↑ "NSF Award Search: Award#1406271 - CAREER: Molecular Diversity in Drug Delivery Design: An Integrated Approach to Research and Education". www.nsf.gov. Retrieved 2020-06-26.
  27. ↑ "Healing lives through Therapeutics | Debra Auguste". Globally Recruit. 2020-02-23. Retrieved 2020-06-26.
  28. ↑ "Bioengineer Debra Auguste awarded Young Faculty Award from DARPA | Harvard John A. Paulson School of Engineering and Applied Sciences". www.seas.harvard.edu. Retrieved 2020-06-26.
  29. ↑ "Engineering Seminar: Biomedical Engineering | School of Engineering". www.brown.edu. Retrieved 2020-06-26.
  30. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Debra T. Auguste - Publications". academictree.org. Retrieved 2020-06-26.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.